FDA Orange Book
Is there a generic for Evotaz?
Evotaz contains atazanavir and cobicistat. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Evotaz (atazanavir and cobicistat). The Orange Book shows its last listed patent expires October 6, 2032.
Run it in Rivvi
Map Evotaz and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Evotaz products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| tablet, oral | EQ 300MG BASE;150MG | Marketed (Rx) | None | 0 | None |
NDA 206353, held by BRISTOL MYERS SQUIBB CO. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Evotaz patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 8148374 | September 3, 2029 | Drug substance, Drug product | U-1279 | 206353 |
| 10039718 | October 6, 2032 | Drug product | None | 206353 |
Evotaz NDC codes
Questions
Is there a generic for Evotaz?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Evotaz (atazanavir and cobicistat). The Orange Book shows its last listed patent expires October 6, 2032.
What is the generic name for Evotaz?
The active ingredient in Evotaz is atazanavir and cobicistat, per the FDA Orange Book.
When does the Evotaz patent expire?
The last patent listed for Evotaz in the Orange Book expires October 6, 2032. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.